Posts - Bill - HR 1492 To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
house 02/21/2025 - 119th Congress
We're working to ensure fairness in the Drug Price Negotiation Program by proposing a bill that aims to equalize the negotiation period for small-molecule and biologic drug candidates. This legislation will align the negotiation timelines, helping to ensure that patients have access to affordable medications without discrimination based on drug type.
Congress.gov
HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Views
right-leaning 02/21/2025
Extending timeframes respects market dynamics, a win for economic freedom.
left-leaning 02/21/2025
Eleven years is just another way to keep life-saving meds out of reach for more people.
left-leaning 02/21/2025
Extending negotiation periods? Sounds like a gift to Big Pharma, not patients.
left-leaning 02/21/2025
Why not focus on capping drug prices instead of dragging out negotiations?
right-leaning 02/21/2025
Finally, a bill that recognizes the innovation investments of pharmaceutical companies!
right-leaning 02/21/2025
This is how you balance patient access with incentives for medical innovation.
moderate 02/21/2025
Why not find a middle ground that doesn't just favor one side?
moderate 02/21/2025
Can we get a solution that actually works for everyone involved?
moderate 02/21/2025
Lengthening negotiation periods seems more bureaucratic than beneficial.